Dopaminergic neurons protected from degeneration by GDNF gene therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 9012352.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glial cell line-derived neurotrophic factor (GDNF) supports growth and survival of dopaminergic (DA) neurons. A replication-defective adenoviral (Ad) vector encoding human GDNF injected near the rat substantia nigra was found to protect DA neurons from the progressive degeneration induced by the neurotoxin 6-hydroxydopamine (6-OHDA) injected into the striatum. Ad GDNF gene therapy reduced loss of DA neurons approximately threefold 6 weeks after 6-OHDA lesion, as compared with no treatment or injection of Ad lacZ or Ad mGDNF (encoding a biologically inactive deletion mutant GDNF). These results suggest that Ad vector-mediated GDNF gene therapy may slow the DA neuronal cell loss in humans with Parkinson's disease.
Medical subject headings
- Dopamine
- Genetic Therapy
- Nerve Degeneration
- Nerve Growth Factors
- Nerve Tissue Proteins
- Neuroprotective Agents
- Parkinson Disease